In this study, neutralizing the individual anxiolytic effects of a low dose of ketamine and MTEP through their combination implies that the NMDAR antagonism by ketamine and the mGluR5 antagonism by MTEP reduce anxiety through distinct molecular pathways, likely involving the activation of the other receptor. This evidence concerns the gene GRM5 and Anxiety.